Prospects Fund

Prospects Oncology Fund

prospect-oncology-fund-imgFACIT’s Prospects Fund is designed to support early stage proof-of-concept (POC) studies within Ontario academic institutions and start-ups that fit with FACIT’s Ontario First Investment Strategy and have the potential to act as deal flow for the Compass Rose Fund. Prospects funding ranges between $50,000 and $200,000.

Funding is governed by a research contract which grants certain rights to FACIT.   FACIT receives no financial consideration on Prospects awards of $50,000 or less (***new limit as of September 2019***).  On all other awards, FACIT receives an option to make an investment at the Compass Rose level and act as the agent for commercialization, if mutually agreed.  If the option is exercised, funding received from the Prospects Fund will be credited towards FACIT's Compass Rose investment.

How to apply:

The Prospects Fund is accepting pre-submission forms twice yearly on the following dates:

  • March 31
  • September 30

The pre-submission form can be downloaded here.

Late applications will not be considered.

Selected applicants will then be invited to prepare a Prospects funding application which is subject to due diligence by FACIT.

Select Prospects Funded Projects

Prospects Fund (Other)

Modeling software to create synthetic data based on real clinical datasets

Replica Analytics is developing modeling software to create synthetic data based on real clinical datasets.

Modeling software to create synthetic data based on real clinical datasetsModeling software to create synthetic data based on real clinical datasets


Algorithm to predict breast cancer patient response to neoadjuvant chemotherapy

Innovative technology consists of specialized hardware and algorithms for analyzing ultrasound RF-data.

Algorithm to predict breast cancer patient response to neoadjuvant chemotherapy Algorithm to predict breast cancer patient response to neoadjuvant chemotherapy


Development of WD40 Repeat Domain (WDR) Platform

OICR is developing a programme targeting multiple members of the WD40 repeat domain (WDR) family with small molecules.

Development of WD40 Repeat Domain (WDR) Platform Development of WD40 Repeat Domain (WDR) Platform


Split Intein-Mediated Protein Ligation (SIMPL): a unique and disruptive system for detecting PPIs in real time

Development of a novel system to trap weak or transient protein-protein interactions (PPIs), unique for its tolerance for multiple experimental conditions and utility for drug discovery application

Split Intein-Mediated Protein Ligation (SIMPL): a unique and disruptive system for detecting PPIs in real timeSplit Intein-Mediated Protein Ligation (SIMPL): a unique and disruptive system for detecting PPIs in real time


View All Prospects Funded Projects